|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
1.330 USD |
+5.56% | +17.70% | +47.03% | |
Published on 06/06/2025 at 17:45
© Reuters – 2025
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule |
Jun. 06 |
RE |
|
Gossamer Bio, Inc., Q1 2025 Earnings Call, May 15, 2025 |
May. 15 |
|
|
Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 15 |
CI |
|
Gossamer Bio Announces Inducement Grant Under |
Apr. 08 |
RE |
|
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 |
Mar. 13 |
CI |
|
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
Mar. 13 |
CI |
|
Gossamer Bio, Inc. Presents at Barclays 27th Annual Global Healthcare Conference 2025, Mar-12-2025 01:00 PM |
Mar. 12 |
|
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) |
Mar. 07 |
RE |
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) |
Feb. 07 |
RE |
|
Earnings Flash (GOSS) GOSSAMER BIO Reports Q3 Revenue $9.5M |
Nov. 07 |
MT |
|
Earnings Flash (GOSS) GOSSAMER BIO Reports Q3 Loss $-0.14 |
Nov. 07 |
MT |
|
Gossamer Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 07 |
CI |
|
Bolt Biotherapeutics, Inc. Announces Changes to Its Board of Directors |
24-09-04 |
CI |
|
Earnings Flash (GOSS) GOSSAMER BIO Reports Q2 Revenue $95.8M |
24-08-12 |
MT |
|
Gossamer Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 |
24-08-12 |
CI |
|
Oppenheimer Initiates Gossamer Bio at Outperform With $9 Price Target |
24-06-25 |
MT |
|
Gossamer Bio, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM |
24-06-12 |
|
|
Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 |
24-05-07 |
CI |
|
Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications |
24-05-06 |
CI |
|
Chiesi Farmaceutici S.p.A., Gossamer Bio, Inc. – M&A Call |
24-05-06 |
|
|
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment |
24-05-06 |
RE |
|
Gossamer Bio Announces Publication of Torrey Phase 2 Results in the Lancet Respiratory Medicine |
24-05-03 |
CI |
|
Gossamer Bio, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM |
24-03-13 |
|
|
Gossamer Bio Announces Board of Directors Appointments |
24-03-12 |
CI |
|
Goldman Sachs Adjusts Price Target on Gossamer Bio to $8 From $9, Maintains Buy Rating |
24-03-06 |
MT |
GOSS: Dynamic Chart
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
More about the company
Buy
Average target price
7.607USD
Spread / Average Target
+471.97%
Consensus
Select your edition
All financial news and data tailored to specific country editions
